Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vaxcyte, Inc. (PCVX) on June 23, 2026, covering events that occurred on June 17, 2026. The filing addresses changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Departure of Director: Jacks Lee retired from the Board of Directors effective June 17, 2026. The retirement was not the result of any disagreement with the Company.
- Consulting Role: Upon retirement, Mr. Lee entered into a consulting agreement to advise on global strategic supply and manufacturing operations.
- Appointment of Director: Moncef Slaoui was appointed to the Board as a Class II director, effective immediately. His term expires at the 2028 annual meeting of stockholders.
- Independence: The Board determined Dr. Slaoui qualifies as an independent director under Nasdaq Rules.
Guidance, Outlook, and Compensation
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. Regarding compensation, Dr. Slaoui will be compensated under the Company's standard non-employee director program. The equivalent value of the annual equity grant for all directors is currently set at $430,000. The Company has also entered into a standard indemnification agreement with Dr. Slaoui.
Key Facts for Investor Verification
- Verify the specific terms of the consulting agreement entered into with Jacks Lee.
- Confirm the details of the Director Compensation Program referenced in the April 23, 2026, Definitive Proxy Statement.
- Review Dr. Moncef Slaoui's background and potential conflicts of interest, though the filing states none exist under Item 404(a).
- Monitor the Company's upcoming 2028 annual meeting for the expiration of Dr. Slaoui's director term.